Artiva Biotherapeutics (ARTV) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($323.9 million vs $323.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | SCTX |
|---|---|---|
| Share price | $6.62 | $17.11 |
| Market cap | $323.41M | $323.92M |
| 1-day change | -5.50% | -2.62% |
| YTD return | +63.17% | — |
| 1-year return | +141.38% | — |
| EPS (TTM) | $-3.23 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $39.60 |
| 52-week low | $2.71 | $13.50 |
| Distance from 52-week high | -54.47% | -56.79% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +441.19% | +233.14% |
| Average volume | 402.33K | 357.50K |
| Shares outstanding | 48.89M | 18.93M |
| Employees | 115 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
ARTV vs SCTX FAQ
Which is bigger, Artiva Biotherapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $323.92M compared with $323.41M for Artiva Biotherapeutics (ARTV).
Are Artiva Biotherapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.